KOLMAR BNHLtd Valuation

Q: What is the Fair Price of A200130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A200130 (₩13080) is trading above our estimate of [[fair value]] (₩5240.64)

Is A200130 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A200130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A200130 (₩13080) is trading above our estimate of fair value (₩5240.64)

Significantly Below Fair Value: A200130 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A200130?

Key metric: As A200130 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A200130. This is calculated by dividing A200130's market cap by their current earnings.
What is A200130's PE Ratio?
PE Ratio	21.5x
Earnings	₩17.77b
Market Cap	₩380.85b

A200130 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	11.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A200130's PE Ratio compare to its peers?

The above table shows the PE ratio for A200130 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	14.1x
A237880 CLIO CosmeticsLtd	8.8x	11.8%	₩314.7b
A226320 It'S Hanbul	16.6x	n/a	₩193.8b
A241710 Cosmecca Korea	15.8x	23.4%	₩562.8b
A078520 Able C&C	15.3x	n/a	₩185.5b
A200130 KOLMAR BNHLtd	21.4x	n/a	₩380.8b

Price-To-Earnings vs Peers: A200130 is expensive based on its Price-To-Earnings Ratio (21.4x) compared to the peer average (14.2x).

Price to Earnings Ratio vs Industry

How does A200130's PE Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A900120 CXI Healthcare Technology Group	0.8x	n/a	US$15.93m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A200130 is expensive based on its Price-To-Earnings Ratio (21.4x) compared to the KR Personal Products industry average (16x).

Price to Earnings Ratio vs Fair Ratio

What is A200130's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A200130 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	21.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A200130's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NOVAREXLtd

₩135.8b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,670.00

-0.1%

-29.5%

Cosmecca Korea

₩562.8b

Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.

A241710

₩52,700.00

-6.2%

47.2%

Cosmax

₩1.5t

Researches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally.

A192820

₩133,100.00

1.4%

16.9%